These studies stated that many pathways such as JAK/STAT and NFкB pathways are involved in the induction of PD-L1; therefore, inhibiting these pathways involved might be therapeutically of value in HCC. This evidence concerns the gene SOAT1 and hepatocellular carcinoma.